CURRENT TRENDS IN THE PHARMACOTHERAPY OF ATOPIC ASTHMA



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Asthma is a common chronic respiratory disease, characterized by different mechanisms and the development of heterogeneous phenotypes. This review discusses the main pharmacotherapy innovations and their possible clinical application.

Full Text

Restricted Access

About the authors

N G Astafieva

Saratov Medical University named after V.I. Rasumovsky

Email: astang@mail.ru
Russia

I V Gamova

Saratov Medical University named after V.I. Rasumovsky

Russia

E N Udovitchenko

Saratov Medical University named after V.I. Rasumovsky

Russia

I A Perfilova

Saratov Medical University named after V.I. Rasumovsky

Russia

D Y Kobzev

Saratov Medical University named after V.I. Rasumovsky

Russia

J M Kenesarieva

Saratov Medical University named after V.I. Rasumovsky

Russia

References

  1. GINA — Global strategy for asthma management and prevention, update 2011. www.ginasthma.org.
  2. Чучалин А.Г. Новые перспективы в терапии бронхиальной астмы. Пульмонология. 2011, № 4, с. 3-6.
  3. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика» (четвертое издание, исправленное и дополненное). М., Изд. дом «Атмосфера», 2011, 108 с.
  4. Астафьева Н.Г. и соавт. Обновленные стратегии лечения и профилактики бронхиальной астмы на основе лучшего понимания проблем воспаления и контроля болезни. Врач. 2011, № 11, с. 8-12.
  5. Shitrit D.Challenges and trends in pulmonary medicine. Harefuah. 2012, v. 151 (4), p. 196-197, 255.
  6. Padden J., Skoner D., Hochhaus G. Pharmacokinetics and pharmacodynamics of inhaled glucocorticoids. Journal of Asthma. 2008, v. 45, p. 13-24.
  7. Sahasranaman S., Issar M., Hochhaus G. Metabolism of mometasone furoate and biological activity of the metabolites. Drug Metab. Dispos. 2006, v. 34, p. 225-233.
  8. Yang T.T. et al. Drug delivery performance of the mometasone furoate dry powder inhaler. J. Aerosol Med. 2001, v. 14, p. 487-494.
  9. D’Urzo A. et al. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr. Med. Res. Opin. 2005, v 21, p. 1281-1289.
  10. Corren J. et al. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int. J. Clin. Pract. 2003, v. 57, p. 567-572.
  11. Bousquet J. et al. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur. Respir. J. 2000, v. 16, p. 808-816.
  12. Wardlaw et al. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. Ann. Allergy Asthma Immunol. 2004, v. 93, p. 49-55.
  13. Fish J.E. et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J. Allergy Clin. Immunol. 2000, v. 106, p. 852-860.
  14. Price D. et al. Improved adherence with oncedaily versus twicedaily dosing of mometasone furoate administered via a dry powder inhaler: a randomized openlabel study. BMC Pulm. Med. 2010, v. 10, p. 19.
  15. Pincus D. et al. Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J. Allergy Clin. Immunol. 1997, v 100, p. 771-774.
  16. Mead J., Takishima T., Leith D. Stress distribution in lungs: a model of pulmonary elasticity. J. Appl. Physiol. 1970, v. 28, p. 596-608.
  17. Woolcock A.J. Effect of drugs on small airways. Am. J. Respir. Crit. Care Med. 1998, v. 157, p. 203-207.
  18. Balzar S., Wenzel S.E., Chu H.W. Transbronchial biopsy as a tool to evaluate small airways in asthma. Eur. Respir. J. 2002, v. 20, p. 254-259.
  19. Айсанов З.Р., Калманова Е.Н., Стулова О.Ю. Циклесонид (Альвеско®) в лечении больных бронхиальной астмой. РМЖ. 2012, № 6, c. 341-344.
  20. Canadian Thoracic Society 2012 guideline update: Diagnosis and management of asthma in preschoolers, children and adults. Can. Respir. J. 2012, v. 19, p. 127-164.
  21. Tovey D. Asthma challenges: The place of inhaled long-acting beta-agonists. Cochrane Database Syst. Rev. 2010, v. 14, p. 8.
  22. Chapman K.R. et al. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax. 2010, p. 65, p. 747-752.
  23. Место препарата Онбрез Бризхалер (индакатерол) в терапии хронической обструктивной болезни легких: заключение экспертного совета под ред. А.Г. Чучалина. Пульмонология. 2011, № 6, с. 124-125.
  24. Cazzola M., Page C.P., Calzetta L., Matera M.G. Pharmacology and Therapeutics of Bronchodilators. Pharmacol. Rev. 2012, v. 64б, p. 450-504.
  25. Cowan K., Guilbert T.W. Pediatric asthma phenotypes. Curr. Opin. Pediatr. 2012, v. 24, p. 344-351.
  26. Watts K., Chavasse R.J. Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database Syst. Rev. 2012, v. 16, p. 5.
  27. Chauhan B.F., Ducharme F.M. Antileukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst. Rev. 2012, v. 16, p. 5:CD002314.
  28. Demissie S., Riekert K.A., Eakin M.N. et al. How Do Perceptions of Asthma Control and Severity Relate to Indicators of Asthma Status and Treatment Recommendations by Pediatricians? Pediatr. Allergy Immunol Pulmonol. 2012, v. 25, p. 17-23.
  29. Robinson C.B., Leonard J., Panettieri R.A. Jr. Drug development for severe asthma: What are the metrics? Pharmacol Ther. 2012, v. 135, p. 176-181.
  30. Pedersen S. From asthma severity to control: a shift in clinical practice. Prim. Care Respir. J. 2010, v. 19, p. 3-9.
  31. O’Byrne P.M., Naji N., Gauvreau G.M. Severe asthma: future treatments. Clin. Exp. Allergy. 2012, v. 42, p. 706-711.
  32. Kennedy J.L., Heymann P.W., Platts-Mills T.A. The role of allergy in severe asthma. Clin. Exp. Allergy. 2012, v. 42, p. 659-669.
  33. Holt P.G., Sly P.D. Viral infections and atopy in asthma pathogenesis: new rationales for asthma prevention and treatment. Nat. Med. 2012, v 4, p. 726-735.
  34. Степанян И.Э. Спирива® Респимат® — препарат нового поколения. РМЖ. 2012, № 6, c. 324.
  35. Apter A.J. Advances in adult asthma diagnosis and treatment and health outcomes, education, delivery, and quality in 2011: what goes around comes around. J. Allergy Clin. Immunol. 2012, v. 129, p. 69-75.
  36. Schatz M. Predictors of asthma control: what can we modify? Curr. Opin. Allergy Clin. Immunol. 2012, v. 12, p. 263-268.
  37. Lougheed M.D., Lemiere C., Ducharme F.M. et al. Canadian Thoracic Society Asthma Clinical Assembly. Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults. Can. Respir. J. 2012, v 19, p. 127-164.
  38. Holgate S.T The airway epithelium is central to the pathogenesis of asthma. Allergol Int. 2008, v. 57, p. 1-10.
  39. Woodruff P.G., Boushey H.A., Dolganov G.M. et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc. Natl. Acad Sci U S A. 2007, v. 104, p. 15858-63.
  40. Kraft M. Asthma Phenotypes and Interleukin-13 — Moving Closer to Personalized Medicine. New England Journal of Medicine. 2011, v. 365, p. 1141-1144.
  41. Thomson Neil C., Patel Manish, Smith Andrew D. Lebrikizumab in the personalized management of asthma. Biologics. 2012, v. 6, p. 329-335.
  42. Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012, v. 18, p. 651-659.
  43. Richeldi L., Ferrara G., Fabbri L.M. et al. Macrolides for chronic asthma. Cochrane Database Syst. Rev. 2005, v. 4, CD002997.
  44. Cameron E.J., McSharry C., Chaudhuri R. et al. Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments. Clin. Exp. Allergy. 2012, v. 42. p 1302-1312.
  45. Mathew J., Aronow W.S., Chandy D. Therapeutic options for severe asthma. Arch. Med. Sci. 2012, v. 8, p. 589-597.
  46. Чучалин А.Г. Новые перспективы в терапии бронхиальной астмы. Пульмонология. 2011, № 4, с. 5-12.
  47. Allergen immunotherapy: A practice parameter second update. Editor: Linda Cox American Academy of Allergy, Asthma & Immunology Allergy Clin. Immunol. 2007, v. 120, p. 25-85.
  48. Sublingual Immunotherapy: World Allergy Organization Position Paper 2009 Allergy. 2009, v. 64, p. 1-59.
  49. Гущин И.С., Курбачева О.М. Аллергия и аллерген-специфическая иммунотерапия. М., «Фармарус Принт Медиа». 2010, 228 с.
  50. Астафьева Н.Г., Горячкина Л.А. Аллерген-специфическая иммунотерапия в клинической практике. М., 2007, 86 с.
  51. Calderon M., Cardona V., Demoly P. One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions Allergy. 2012, v. 67, p. 462-476.
  52. Neske F., Schorner C., Buchheit K.H., Costanzo A., Hanschmann K.M., Himly M. et al. BSP090 the follow-up to CREATE. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2009, v. 96, p. 12-19.
  53. Астафьева Н.Г., Гамова И.В., Удовиченко Е.Н. и соавт. Место аллерген-специфической иммунотерапии в лечении атопии. Эффективная фармакотерапия. Аллергология и иммунология. 2012, № 1, с. 6-16.
  54. Calderon M.A., Gerth van Wijk R., Eichler I. et al. Perspectives on allergen-specific immunotherapy in childhood: An EAACI position statement. Pediatr Allergy Immunol. 2012, v. 23, p. 300-306.
  55. Calderon M., Cardona V., Demoly P. One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions Allergy. 2012, v. 67, p. 462-476.
  56. Linhart B., Valenta R. Vaccines for allergy. Curr. Opin. Immunol. 2012, v. 24, p. 354-360.
  57. Valenta R., Campana R., Marth K., van Hage M. Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. J. Intern. Med. 2012, v. 272, p. 144-157.
  58. Akdis C.A.Therapies for allergic inflammation: refining strategies to induce tolerance. Nat. Med. 2012, v. 4, p. 736-749.
  59. Linhart B., Valenta R. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine. 2012, v. 19, p. 4328-4335.
  60. Barnes P.J. New drugs for asthma. Semin. Respir. Crit. Care Med. 2012, v. 33, p. 685-694.

Copyright © Pharmarus Print Media, 2013



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies